Filtered By:
Management: WHO
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 401 results found since Jan 2013.
Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019
The novel coronavirus disease 2019 (COVID-19) emerged from Wuhan, People ’s Republic of China, in December 2019, and by March 2020, it was recognized as a global pandemic by the World Health Organization. The speed with which the disease has spread and its sizable case fatality have led to the clinical application of various therapies with at most minimal evidence of e fficacy or safety. This is of renewed and persistent importance as the number of polymerase chain reaction–positive cases of COVID-19 continues to increase in much of the United States of America.
Source: Annals of Allergy, Asthma and Immunology - November 4, 2020 Category: Allergy & Immunology Authors: Nicholas Hartog, Amanda Holsworth, Surender Rajasekaran Tags: Perspective Source Type: research
Controlled Trials Needed to Prove Efficacy and Safety of Convalescent Plasma Therapy in COVID-19
The novel coronavirus disease (COVID-19) emerged from Wuhan, China in December 2019 and by March 2020 was recognized as a global pandemic by the World Health Organization. The speed with which the disease has spread, and its sizable case fatality have led to the clinical application of various therapies with at most minimal evidence of efficacy or safety.
Source: Annals of Allergy, Asthma and Immunology - November 4, 2020 Category: Allergy & Immunology Authors: Nicholas Hartog, Amanda Holsworth, Surender Rajasekaran Tags: Perspective Source Type: research
Remdesivir Is the First FDA-Approved Treatment for COVID-19
On Oct. 22, the Food and Drug Administration (FDA) approved the first drug for treating COVID-19.
Remdesivir, an antiviral medication given intravenously, is now approved for anyone hospitalized with COVID-19. It works by blocking the virus’s ability to make more copies of itself. Earlier this year, the drug had received emergency use authorization (EUA), which falls short of approval but is granted during a public health crisis if there is encouraging data supporting its potential benefits. Approval means the drug’s maker, Gilead, provided more information to the FDA on the medication’s effectiveness and...
Source: TIME: Health - October 22, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
What the Conflicting Results on Promising COVID-19 Drug Remdesivir Really Mean
Treating any infectious disease is a high wire act—doctors must balance the risks and benefits of therapies with the risks of the disease. And those stakes are even higher for a new disease that doesn’t yet have a playbook for physicians to follow.
This summer, the U.S. Food and Drug Administration gave the drug remdesivir emergency use authorization for treating any patients hospitalized with COVID-19. But on Oct.15, researchers working on the World Health Organization’s (WHO) Solidarity trial published a preliminary report showing that nearly 3,000 people receiving the treatment were not more likely to ...
Source: TIME: Health - October 19, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Variable Clinical Manifestations of COVID-19: Viral and Human Genomes Talk.
Abstract
The new coronavirus, known as "SARS-CoV-2"; is the cause of one of the most prevalent infectious viral diseases that was recently announced pandemic by the world health organization. Ongoing research in the fields of prevention, management, and therapy establishes a functional scaffold for clinics during the time of crisis. To obtain this goal, it is necessary that all pathophysiologic aspects of COVID-19 from infection to predisposing backgrounds of infection be identified, so that all the ambiguities of researchers regarding transmission mechanisms, variable clinical manifestation, and therapeutic respo...
Source: Iranian Journal of Allergy, Asthma and Immunology - October 18, 2020 Category: Allergy & Immunology Authors: Imani-Saber Z, Vaseghi H, Mahdian M, Safari F, Ghadami M Tags: Iran J Allergy Asthma Immunol Source Type: research
A Proposal From The Montpellier World Health Organization Collaborating Centre For Better Management And Prevention Of Anaphylaxis
Publication date: Available online 13 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Luciana Kase Tanno, Nidhal Touati, Salome Allichon, Bryan Martin, Motohiro Ebisawa, Ignacio Ansotegui, Mario Sanchez-Borges, Victoria Cardona, Paul A. Greenberger, Dermot Ryan, Guillaume Pouessel, Etienne Beaudouin, Jean-Marie Renaudin, Francis Thiens, Yoon-Seok Chang, Ruby Paw.ar, Maximiliano Gomez, Edgardo Jares, Patricia Latour Staffeld, Ioana Agache
Source: The Journal of Allergy and Clinical Immunology: In Practice - October 14, 2020 Category: Allergy & Immunology Source Type: research
Tragic Math: The U.S. Exceeds 200,000 COVID-19 Deaths
Body count has long been the yardstick by which we measure calamity. There were the 58,000 U.S. lives lives lost in the Vietnam war; the 1,496 souls who perished on the Titanic. In the hours after the September 11 attacks, when the death toll was not known, then-New York Mayor Rudy Giuliani famously said, “The number of casualties will be more than any of us can bear, ultimately.”
We are, once again, trying to bear the unbearable as the U.S. today surpassed 200,000 deaths caused in the still-rampaging COVID-19 pandemic. We remain, as we have long been, the world’s hardest-hit country, with just 4% of the ...
Source: TIME: Health - September 22, 2020 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news
The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins.
Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news
Why the U.S. Is Losing the War On COVID-19
It is a frightening time to live in the United States. COVID-19, a novel disease as ruthless as it is seemingly random, is picking us off by the thousands; even many of those who “recover” may never truly be the same again. The pandemic has exposed the gulf between what this country promises for its citizens and what it actually delivers. And as the U.S. barrels toward Election Day, the outbreak is sure to complicate the voting process, with potentially disastrous results.
For a short time in the spring, it appeared the U.S. was getting a grip on its outbreak. Hard-hit states like New York successfully flattene...
Source: TIME: Science - August 13, 2020 Category: Science Authors: Alex Fitzpatrick Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news
Johnson & Johnson Announces European Commission Approval for Janssen ’s Preventive Ebola Vaccine
Discussions with the U.S. Food and Drug Administration (FDA) have taken place to define the required data set for filing US licensure. About Janssen’s Ebola Vaccine Regimen The Janssen preventive Ebola vaccine regimen, Ad26.ZEBOV and MVA-BN-Filo, utilizes a non-replicating viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors carry the genetic code of several Ebola virus proteins in order to trigger an immune response.Janssen’s vaccine regimen ori...
Source: Johnson and Johnson - July 1, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Covid-19 Is Not Gender-Neutral
By Andrea UlrichJune 09, 2020As people around the world continue to face the effects of COVID-19, academic institutions and government policymakers are turning to data more than ever to understand the scope of the crisis, anticipate its spread, and formulate policy decisions.One example of existing high quality, real-time data is theJohns Hopkins’ COVID-19 dashboard, which has expanded as a data resource as the crisis grows. While policymakers and experts are relying on these resources, it is crucial to understand what information is being captured and what is not, as making decisions with incomplete or faulty data h...
Source: IntraHealth International - June 8, 2020 Category: International Medicine & Public Health Authors: cbishopp Tags: COVID-19 Digital Health Source Type: news
Coronavirus Vaccine: Here Are The Latest Developments
(CNN) — While coronavirus keeps spreading and killing with impunity, the world waits for a vaccine that could quash the pandemic.
But details and timelines keep shifting. Here’s the latest on where we stand in the race for a vaccine:
When will a Covid-19 vaccine be available to the public?
No one’s sure yet, but the target is sometime in early 2021.
Vaccines in development around the world are in various stages of testing. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he’s confident one of the vaccine candidates will be proven safe and effective by th...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 8, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Closures Covid-19 Boston, MA Health Healthcare Status Coronavirus Coronavirus Vaccine Moderna Therapeutics Source Type: news
Johnson & Johnson Receives Positive CHMP Opinion for Janssen ’s Investigational Preventive Ebola Vaccine Regimen
Discussions with the FDA are ongoing to define the required data set for filing Janssen’s Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. About Janssen’s Ebola Vaccine Regimen The Janssen investigational preventive Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely carry the genetic code of an Ebola virus protein in order to trigger an immun...
Source: Johnson and Johnson - May 29, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma —implications for COVID-19
Coronavirus disease 2019 (COVID-19) is caused by a novel zoonotic coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has been identified as a pandemic by the World Health Organization. Several risk factors have been identified for severe COVID-19 –associated pneumonia including increased age and the presence of comorbidities, in particular diabetes, cardiovascular disease, and tobacco smoking.1 However, a number of reports have failed to identify excess risk in patients with respiratory airway diseases such as asthma.
Source: Journal of Allergy and Clinical Immunology - May 21, 2020 Category: Allergy & Immunology Authors: Peter Bradding, Matthew Richardson, Timothy S.C. Hinks, Peter H. Howarth, David F. Choy, Joseph R. Arron, Sally E. Wenzel, Salman Siddiqui Tags: Letter to the Editor Source Type: research
